![conference banner](/images/conference-banner.jpeg)
Abstract
Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis. Statins are widely and successfully used for lowering plasma cholesterol levels causing up to 45% reduction of plasma cholesterol and considerable reduction in risk of cardiovascular diseases. The main atheroprotective action of statins is reduction of plasma low density lipoprotein levels due to improved clearance of this lipoprotein by the liver. In addition, statins cause mild elevation of high density lipoprotein (HDL) concentration, but the mechanism responsible for this effect of statins on HDL metabolism is not well understood. It has been hypothesized that statins affect the HDL level through inhibition of cholesteryl ester transfer protein activity or by stimulating apolipoprotein A-I synthesis. Increased cholesterol efflux from liver due to raised expression of the ABCA1 transporter may also elevate HDL levels. Whereas raising the plasma HDL-C concentration may contribute to the atheroprotective effect of statins, its magnitude is uncertain and additional mechanisms that improve the functionality of HDL may be equally or more important. In this review we analyze what is currently known about effect of statins on HDL metabolism and on reverse cholesterol transport in particular.
Keywords: Statins, high density lipoprotein, apolipoprotein A-I, lipoproteins, atherosclerosis, coronary artery disease, risk factors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Statins and Metabolism of High Density Lipoprotein
Volume: 5 Issue: 3
Author(s): Dmitri Sviridov, Paul Nestel and Gerald Watts
Affiliation:
Keywords: Statins, high density lipoprotein, apolipoprotein A-I, lipoproteins, atherosclerosis, coronary artery disease, risk factors
Abstract: Statins are competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis. Statins are widely and successfully used for lowering plasma cholesterol levels causing up to 45% reduction of plasma cholesterol and considerable reduction in risk of cardiovascular diseases. The main atheroprotective action of statins is reduction of plasma low density lipoprotein levels due to improved clearance of this lipoprotein by the liver. In addition, statins cause mild elevation of high density lipoprotein (HDL) concentration, but the mechanism responsible for this effect of statins on HDL metabolism is not well understood. It has been hypothesized that statins affect the HDL level through inhibition of cholesteryl ester transfer protein activity or by stimulating apolipoprotein A-I synthesis. Increased cholesterol efflux from liver due to raised expression of the ABCA1 transporter may also elevate HDL levels. Whereas raising the plasma HDL-C concentration may contribute to the atheroprotective effect of statins, its magnitude is uncertain and additional mechanisms that improve the functionality of HDL may be equally or more important. In this review we analyze what is currently known about effect of statins on HDL metabolism and on reverse cholesterol transport in particular.
Export Options
About this article
Cite this article as:
Dmitri Sviridov , Paul Nestel and Gerald Watts , Statins and Metabolism of High Density Lipoprotein, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (3) . https://dx.doi.org/10.2174/187152507781058672
DOI https://dx.doi.org/10.2174/187152507781058672 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intervention and Observational Trials are Complementary in Metabolomics: Diabetes and the Oral Glucose Tolerance Test
Current Topics in Medicinal Chemistry Hydrogen Sulfide and Inflammatory Joint Diseases
Current Drug Targets Quality Assessment of Wheat Bread with Microbial Transglutaminase Supplemented with Hull-Less Barley Flour
Current Nutrition & Food Science Genetic Interactions Effects of Cardiovascular Disorder Using Computational Models: A Review
Current Biotechnology The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism Inappropriate Use of Proton Pump Inhibitor Among Elderly Patients in British Columbia: What are the Long-term Adverse Events?
Current Drug Safety Colesevelam: A New and Improved Bile Acid Sequestrant?
Current Pharmaceutical Design Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Current Molecular Medicine Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Current Vascular Pharmacology Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Repurposing Metformin for Vascular Disease
Current Medicinal Chemistry Mitochondria in Chronic Liver Disease
Current Drug Targets Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism The Role of Biomechanical Factors on Patellofemoral Osteoarthritis
Current Rheumatology Reviews